"""
Question: 1101

Evidence: We then constructed a library of 95 mutants of HIV-2ROD9 that contained single or multiple amino acid changes in the integrase protein. Each variant was tested for susceptibility to raltegravir and dolutegravir using a single- cycle indicator cell assay.

Rationale: The paper explicitly states that the authors constructed a library of 95 site-directed mutants of HIV-2ROD9 and tested each variant for drug susceptibility. This describes the generation and analysis of new, previously unpublished experimental data.

Answer: Yes
"""

"""
Question: 1102

Evidence: We also compiled a list of all integrase sequences from INI-treated, HIV-2--infected patients that were available in the National Center for Biotechnology Information GenBank database (see Supplementary Methods for search terms and inclusion criteria). The resultant collection contained 80 group A, 24 group B, 1 CRF01_AB, and 2 group H sequences, including 6 group A sequences from samples that were obtained prior to the initiation of INI-based ART ( Supplementary Table 3 ).

Rationale: The paper describes compiling and analyzing existing HIV-2 integrase sequences from the GenBank database, which constitutes reporting HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: No sentences found.

Rationale: After a thorough review of the provided paper content, there is no mention of in vitro passage experiments. The methods describe site-directed mutagenesis and single-cycle drug susceptibility assays, not the serial passage of virus under drug pressure.

Answer: No
"""

"""
Question: 1104

Evidence: Each variant was tested for susceptibility to raltegravir and dolutegravir using a single- cycle indicator cell assay. Half maximum effective concentration (EC50) values were calculated from semilog plots of the dose-response data using the sigmoidal regression function of Prism version 6.0h (GraphPad Software).

Rationale: The paper explicitly details that each constructed viral variant was tested for drug susceptibility in an assay, and that the half maximum effective concentration (EC50) values were calculated from the resulting dose-response data. This is a direct report of in vitro antiretroviral susceptibility data.

Answer: Yes
"""

"""
Question: 2101

Evidence: No sentences found.

Rationale: The paper mentions compiling sequences from GenBank but does not list or report any specific GenBank accession numbers for any HIV isolates, including laboratory isolates, within the provided text.

Answer: No
"""

"""
Question: 2102

Evidence: No sentences found.

Rationale: The paper mentions compiling sequences from GenBank but does not list or report any specific GenBank accession numbers for any HIV isolates, whether they are laboratory or clinical isolates.

Answer: No
"""

"""
Question: 2103

Evidence: No sentences found.

Rationale: The paper does not list any specific GenBank accession numbers in the provided content.

Answer: NA
"""

"""
Question: 2202

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles ( Supplementary Table 2 ). We then catalogued the amino acid differences present in each patient sequence (relative to the appropriate reference isolate) at each of 41 codon sites.

Rationale: The paper describes extracting genotypes (which imply lists of mutations) from 91 individuals and cataloging amino acid differences in patient sequences, indicating that lists of mutations for individual sequenced isolates were compiled and reported, even if the full lists are in supplementary tables.

Answer: Yes
"""

"""
Question: 2301

Evidence: Public health campaigns to control human immunodeficiency virus (HIV) infection at the population level implicitly include HIV type 2 (HIV-2), which is endemic in West Africa and, like HIV-1, is a causative agent of AIDS [1–3]. The resultant collection contained 80 group A, 24 group B, 1 CRF01_AB, and 2 group H sequences.

Rationale: The paper explicitly states its focus is on HIV-2 and provides a breakdown of the groups (A, B, CRF01_AB, H) of HIV-2 sequences analyzed.

Answer: HIV-2
"""

"""
Question: 2302

Evidence: The resultant collection contained 80 group A, 24 group B, 1 CRF01_AB, and 2 group H sequences.

Rationale: This sentence directly lists the subtypes (referred to as groups in HIV-2) of the sequenced viruses reported from the GenBank compilation.

Answer: group A, group B, CRF01_AB, group H
"""

"""
Question: 2303

Evidence: We then catalogued the amino acid differences present in each patient sequence (relative to the appropriate reference isolate) at each of 41 codon sites. Based on these sources... we selected 31 amino acid changes in HIV-2 integrase for SDM and phenotypic evaluation.

Rationale: The entire genetic analysis and site-directed mutagenesis focus on mutations in the integrase protein. The cataloging of amino acid differences and the selection of mutations for evaluation are specifically for the integrase gene.

Answer: integrase
"""

"""
Question: 2304

Evidence: We then catalogued the amino acid differences present in each patient sequence (relative to the appropriate reference isolate) at each of 41 codon sites. Based on these sources... we selected 31 amino acid changes in HIV-2 integrase for SDM and phenotypic evaluation.

Rationale: The pol gene encodes the integrase protein. The paper reports on the analysis of sequences and mutations specifically within the integrase region of the pol gene.

Answer: Yes
"""

"""
Question: 2401

Evidence: HIV-2, which is endemic in West Africa. We also compiled a list of all integrase sequences from INI-treated, HIV-2--infected patients that were available in the National Center for Biotechnology Information GenBank database.

Rationale: The paper states that HIV-2 is endemic in West Africa, providing a general geographic region. However, it does not specify the geographic origins of the individual sequences compiled from GenBank or the literature beyond this general association.

Answer: West Africa (general association, specific countries not listed)
"""

"""
Question: 2402

Evidence: No sentences found.

Rationale: The provided text does not mention the specific years during which the sequenced samples were obtained.

Answer: NA
"""

"""
Question: 2502

Evidence: For each mutant clone, the sequence of the integrase-encoding region was confirmed by automated Sanger DNA sequencing (Genewiz).

Rationale: The paper explicitly states that Sanger sequencing was used to confirm the sequences of the site-directed mutants created for the study.

Answer: Yes
"""

"""
Question: 2503

Evidence: No sentences found.

Rationale: The paper only mentions Sanger sequencing for confirming mutant clones. There is no reference to the use of Next-Generation Sequencing (NGS) technologies.

Answer: No
"""

"""
Question: 2504

Evidence: Stocks of wild-type and mutant viruses were generated by transient transfection of 293T/17 cells as previously described [32, 33]; see Supplementary Methods for additional details.

Rationale: The generation of virus stocks via transient transfection of plasmids containing the viral genome inherently involves molecular cloning. The site-directed mutants were created in plasmid clones (pROD9).

Answer: Yes
"""

"""
Question: 2505

Evidence: No sentences found.

Rationale: The paper describes site-directed mutagenesis on plasmid clones and transient transfection to produce virus stocks. It does not mention single genome sequencing (SGS) or a similar method for the original patient sequences or the generated mutants.

Answer: No
"""

"""
Question: 2506

Evidence: SDM was performed using full-length pROD9 or pNL4-3 as the plasmid template. Stocks of wild-type and mutant viruses were generated by transient transfection of 293T/17 cells.

Rationale: The process of site-directed mutagenesis (SDM) is performed on plasmid DNA clones (pROD9, pNL4-3). The generation of virus from these plasmids is a form of molecular cloning.

Answer: Yes
"""

"""
Question: 2601

Evidence: No sentences found.

Rationale: The paper compiles sequences from GenBank and the literature from INI-treated patients, but it does not specify the source material (e.g., plasma vs. PBMC) for those sequences within the provided text.

Answer: NA
"""

"""
Question: 2602

Evidence: No sentences found.

Rationale: The paper compiles sequences from GenBank and the literature from INI-treated patients, but it does not specify the source material (e.g., plasma vs. PBMC) for those sequences within the provided text.

Answer: NA
"""

"""
Question: 2603

Evidence: No sentences found.

Rationale: The paper does not provide a count of samples that underwent plasma virus sequencing.

Answer: NA
"""

"""
Question: 2604

Evidence: No sentences found.

Rationale: The paper does not provide a count of samples that underwent PBMC virus sequencing.

Answer: NA
"""

"""
Question: 2605

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles ( Supplementary Table 2 ).

Rationale: The sequences analyzed were from individuals who were receiving INI-based ART, which implies active HIV replication was occurring, as treatment is used to suppress replication in infected individuals.

Answer: Yes
"""

"""
Question: 2606

Evidence: No sentences found.

Rationale: The paper does not state that sequences were obtained from the proviral DNA reservoir. The focus is on sequences from treated individuals, which could be from either plasma RNA or PBMC DNA, but the specific source is not clarified.

Answer: NA
"""

"""
Question: 2701

Evidence: No sentences found.

Rationale: The paper does not mention the age (infant, child, adult) of the individuals from whom the compiled sequences were obtained.

Answer: NA
"""

"""
Question: 2702

Evidence: single-arm clinical trials conducted in France [13] and Senegal [14] indicate that raltegravir- and elvitegravir-containing regimens, respectively, are effective in ART-naive, HIV-2–infected patients.

Rationale: The paper references clinical trials, indicating that some of the individuals whose data was compiled in the literature were part of clinical trials.

Answer: Yes
"""

"""
Question: 2703

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles.

Rationale: The data is compiled from multiple published studies, which would include a mix of individuals from various settings, not exclusively from clinical trials. The mention of clinical trials is as examples among other sources.

Answer: No
"""

"""
Question: 3101

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles ( Supplementary Table 2 ). The resultant collection contained 80 group A, 24 group B, 1 CRF01_AB, and 2 group H sequences.

Rationale: The paper provides two numbers: 91 individuals from the literature review and 107 sequences (80+24+1+2) from the GenBank compilation. As there is partial overlap noted, the total number of unique individuals is not specified, but the paper reports on sequences from at least 91 individuals.

Answer: At least 91 (from literature), and 107 sequences from GenBank with noted overlap.
"""

"""
Question: 3102

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles.

Rationale: The paper reports on sequences extracted from published studies of 91 INI-treated individuals, implying that these individuals underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: including 6 group A sequences from samples that were obtained prior to the initiation of INI-based ART.

Rationale: The paper explicitly mentions sequences from 6 individuals obtained before starting INI-based ART, which implies they were ART-naive with respect to integrase inhibitors at that timepoint.

Answer: Yes
"""

"""
Question: 4102

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles ( Supplementary Table 2 ). Most of the HIV-2 patients in these studies were treated with a regimen that contained raltegravir (n = 80).

Rationale: The vast majority of the sequences compiled are explicitly from individuals who were receiving INI-based treatment, meaning they were ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: Genotypes from 91 INI-treated individuals were extracted... including 6 group A sequences from samples that were obtained prior to the initiation of INI-based ART.

Rationale: The paper reports sequences from both ART-experienced individuals (the 91 treated with INIs) and a smaller number of ART-naive individuals (the 6 pre-INI therapy).

Answer: Yes
"""

"""
Question: 4104

Evidence: including 6 group A sequences from samples that were obtained prior to the initiation of INI-based ART.

Rationale: The paper specifically states that there were 6 sequences from samples obtained before starting INI-based ART.

Answer: 6
"""

"""
Question: 4105

Evidence: No sentences found.

Rationale: The paper compiles data from numerous external studies and GenBank. It does not claim to provide complete ART history for every individual whose sequence was included in the analysis.

Answer: No
"""

"""
Question: 4201

Evidence: No sentences found.

Rationale: The paper focuses on resistance mutations associated with treatment failure, not on the prevalence of transmitted drug resistance in newly infected, untreated individuals.

Answer: No
"""

"""
Question: 4202

Evidence: No sentences found.

Rationale: The paper focuses on resistance mutations emerging during treatment. While it includes 6 pre-INI therapy sequences, it does not analyze or report the prevalence of pretreatment drug resistance in these or other individuals.

Answer: No
"""

"""
Question: 4301

Evidence: Most of the HIV-2 patients in these studies were treated with a regimen that contained raltegravir (n = 80); 2 patients received dolutegravir-based ART without prior treatment with an INI, and 6 initially received raltegravir, but were switched to a dolutegravir-containing regimen prior to sample collection. The remaining patients received either elvitegravir (n = 1) or an unspecified INI (n = 2).

Rationale: The paper specifies that the individuals from the compiled studies received integrase inhibitors (RAL, DTG, EVG). It does not provide detailed information on other drug classes (e.g., NRTIs, PIs) received by these individuals.

Answer: Integrase Inhibitors (specifically Raltegravir, Dolutegravir, Elvitegravir)
"""

"""
Question: 4302

Evidence: Genotypes from 91 INI-treated individuals were extracted from the final collection of 19 research articles. Most of the HIV-2 patients in these studies were treated with a regimen that contained raltegravir (n = 80); 2 patients received dolutegravir-based ART... and 6 initially received raltegravir, but were switched to a dolutegravir-containing regimen.

Rationale: The paper's entire focus is on individuals who received integrase inhibitors (INIs), as it compiles genotypes from INI-treated individuals.

Answer: Yes
"""

"""
Question: 4303

Evidence: No sentences found.

Rationale: The paper does not provide specific information on whether individuals received protease inhibitors. The focus is exclusively on integrase inhibitors and resistance.

Answer: NA
"""

"""
Question: 4304

Evidence: Most of the HIV-2 patients in these studies were treated with a regimen that contained raltegravir (n = 80); 2 patients received dolutegravir-based ART... and 6 initially received raltegravir, but were switched to a dolutegravir-containing regimen. The remaining patients received either elvitegravir (n = 1) or an unspecified INI (n = 2).

Rationale: The paper shows that individuals received different INIs (raltegravir, dolutegravir, elvitegravir) and some switched regimens, indicating they did not all receive the same ART.

Answer: No
"""

"""
Question: 4305

Evidence: 2 patients received dolutegravir-based ART without prior treatment with an INI. 6 initially received raltegravir, but were switched to a dolutegravir-containing regimen prior to sample collection.

Rationale: The paper describes two patients who were INSTI-naive before starting dolutegravir, and six who were switched from raltegravir to dolutegravir. This indicates that not all individuals were INSTI-naive; many had prior raltegravir exposure.

Answer: No
"""

"""
Question: 4403

Evidence: No sentences found.

Rationale: The paper does not provide information on how many individuals received more than one ART regimen.

Answer: NA
"""

"""
Question: 4404

Evidence: No sentences found.

Rationale: The paper does not provide information on how many individuals received more than two ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: No sentences found.

Rationale: The paper does not provide information to determine if all individuals received the same number of ART regimens.

Answer: NA
"""

"""
Question: 4406

Evidence: No sentences found.

Rationale: The paper does not provide information to determine if all individuals received only one ART regimen.

Answer: NA
"""

"""
Question: 4501

Evidence: 2 patients received dolutegravir-based ART without prior treatment with an INI, and 6 initially received raltegravir, but were switched to a dolutegravir-containing regimen prior to sample collection.

Rationale: The paper specifies that 2 patients received dolutegravir as their first INI, and 6 were switched to a dolutegravir-containing regimen, making a total of 8 patients who received dolutegravir.

Answer: 8
"""

"""
Question: 4502

Evidence: No sentences found.

Rationale: The paper does not mention the use of darunavir or any other specific protease inhibitor.

Answer: NA
"""

"""
Question: 5101

Evidence: No sentences found.

Rationale: The paper analyzes the phenotypic effect of specific mutations but does not provide a count of how many individuals from the compiled studies were found to have one or more drug resistance mutation.

Answer: NA
"""

"""
Question: 5102

Evidence: No sentences found.

Rationale: The paper analyzes the phenotypic effect of specific INSTI-resistance mutations but does not provide a count of how many individuals from the compiled studies were found to have them.

Answer: NA
"""

"""
Question: 5103

Evidence: No sentences found.

Rationale: The paper focuses exclusively on integrase inhibitor resistance and does not mention tenofovir (TDF) or TDF-resistance mutations.

Answer: NA
"""

"""
Question: 5104

Evidence: These included K46R, I84V, Q91R, A119T, V141I, A153G, A153S, HI'll continue from question 5104.

"""
Question: 5104

Evidence: These included K46R, I84V, Q91R, A119T, V141I, A153G, A153S, H156R, H157Q, H157R, N160K, and insertions of up to 5 amino acids at position 231 [10, 17, 19, 20, 22, 23, 28]. We also considered combinations of primary INI resistance mutations as potential alternative paths to INI resistance.

Rationale: The paper provides a comprehensive list of INSTI-resistance mutations that were identified in HIV-2 sequences from INI-treated patients, including both primary mutations (Y143C/G/H/R, Q148H/K/R, N155H) and numerous secondary mutations unique to HIV-2.

Answer: Y143C/G/H/R, Q148H/K/R, N155H, K46R, I84V, Q91R, A119T, V141I, A153G/S, H156R, H157Q/R/S/Y, N160K, and insertions at position 231 (SREGK, SREGR)
"""

"""
Question: 6101

Evidence: Each variant was tested for susceptibility to raltegravir and dolutegravir using a single- cycle indicator cell assay.

Rationale: The paper explicitly states that phenotypic susceptibility testing was performed using a single-cycle indicator cell assay.

Answer: Single-cycle indicator cell assay
"""

"""
Question: 6102

Evidence: Half maximum effective concentration (EC50) values were calculated from semilog plots of the dose-response data.

Rationale: The paper reports using EC50 (half maximum effective concentration) values, which are a type of IC (inhibitory concentration) value, specifically the concentration that gives half-maximal response.

Answer: Yes (EC50)
"""

"""
Question: 6103

Evidence: All HIV-1 NL4-3 and HIV-2 ROD9 mutants were subjected to at least 3 independent determinations of raltegravir and dolutegravir susceptibility. Log10-transformed EC50 values were subjected to an analysis of variance (ANOVA) with Tukey multiple comparisons test.

Rationale: The paper describes calculating EC50 values for mutants and comparing them to wild-type, which inherently involves reporting fold-change values (mutant EC50 / wild-type EC50). The statistical analysis of log-transformed EC50 values confirms this approach.

Answer: Yes
"""

"""
Question: 6104

Evidence: Each variant was tested for susceptibility to raltegravir and dolutegravir using a single- cycle indicator cell assay. After approximately 40 hours of infection, the MAGIC-5A monolayers were lysed using a nonionic detergent solution, and β-galactosidase activity was measured by treating the lysates with chlorophenol red-β-d-galactopyranoside.

Rationale: The paper provides specific details about the phenotypic assay used: a single-cycle assay using MAGIC-5A indicator cells with β-galactosidase activity measured via CPRG substrate conversion.

Answer: Single-cycle indicator cell assay using MAGIC-5A cells with β-galactosidase reporter
"""

"""
Question: 6105

Evidence: No sentences found.

Rationale: While the paper mentions that some mutants showed poor replication capacity in a previous study, it does not systematically report replication capacity data for the mutants in the current study.

Answer: No
"""

"""
Question: 6106

Evidence: Each variant was tested for susceptibility to raltegravir and dolutegravir using a single- cycle indicator cell assay.

Rationale: The paper explicitly states that two drugs were tested in the phenotypic susceptibility assays: raltegravir and dolutegravir.

Answer: Raltegravir and Dolutegravir
"""

"""
Question: 7101

Evidence: We then constructed a library of 95 full-length, site-directed mutants of HIV-2ROD9, each containing up to 6 amino acid replacements in the integrase protein. SDM was performed using full-length pROD9 or pNL4-3 as the plasmid template and synthetic oligonucleotides.

Rationale: The entire experimental approach of the paper is based on creating and testing site-directed mutants of HIV-2ROD9 and HIV-1NL4-3.

Answer: Yes
"""

"""
Question: 7102

Evidence: No sentences found.

Rationale: The paper describes site-directed mutagenesis and single-cycle drug susceptibility testing, but does not mention any in vitro passage experiments where virus was serially passaged under drug pressure to select for resistance.

Answer: No
"""